# Fondaparinux

## Arixtra 2.5mg/0.5mL pre-filled syringe

##### 

| TAH Drug Code      | IARI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|:-------------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Deep venous thrombosis, acute, In conjunction with warfarin sodium ‧Postoperative deep vein thrombosis, Hip repair or replacement, knee replacement, or abdominal surgery; Prophylaxis ‧Pulmonary embolism, acute, In conjunction with warfarin sodium when initial therapy is administered in a hospital                                                                                                                                                                                                                                                                                  |
| Dosing             | For patients undergoing lower extremity surgery or abdominal surgery, SC 2.5mg once daily for 5-9 days. The first dose must be gievn 6 hours after surgery and stop bleeding. For UA/NSTEMI, SC 2.5mg daily for 8 days or discharge. Maximum 8 days. For STEMI, IV 2.5mg as first dose, followed by SC 2.5mg once daily to 8 days or dischrage. Maximum 8 daysFor DVT and PE, SC once daily with dose of 5mg for weight < 50kg, 7.5mg for weight between 50-100 kg and 10mg for weight beyond 100 kg, combination with warfarin sodium within 72 hours, for at least 5 days, up to 9 days. |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Contraindications  | ‧Active major bleeding ‧Bacterial endocarditis ‧Body weight less than 50 kg in patients requiring prophylaxis for venous thromboembolism ‧History of serious hypersensitivity reaction (eg, angioedema, anaphylactoid or anaphylactic reactions) ‧Severe renal impairment (ie, CrCl less than 30 mL/minute) ‧Thrombocytopenia associated with positive in vitro test for antiplatelet antibody in the presence of fondaparinux sodium                                                                                                                                                      |
| Adverse Effects    | Common ‧Dermatologic: Injection site reaction, Rash (7.5% ) ‧Other: Fever (13.6% ) Serious ‧Hematologic: Anemia (perioperative prophylaxis, 19.6%; extended prophylaxis, 1.5% ), Hemorrhage (2.2% to 3.4% ), Thrombocytopenia (0.04% to 0.2% (less than 50,000/mm(3)); 0.5% to 3% (50,000 to 100,000/mm(3)) ) ‧Immunologic: Anaphylaxis, Hypersensitivity reaction ‧Neurologic: Extradural intracranial hematoma, Non-traumatic spinal subdural hematoma                                                                                                                                   |
| Pregnancy          | No Data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |

